Developer docs
API playgroundTry for free, no card

Search company profiles

Ziwig

Full company profile

uuid0006u7r

Namestring
Ziwig
Legal namestring
ZIWIG
Websiteurl
ziwig.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Ziwig is a French biotech company founded in 2019 and headquartered in Lyon, France, specializing in women's health diagnostics through salivary RNA analysis combined with artificial intelligence. The company's flagship product, Ziwig Endotest®, is the first in vitro diagnostic medical device for endometriosis using a saliva sample, employing a proprietary 109-miRNA signature analyzed via next-generation sequencing (NGS) and interpreted by machine learning algorithms. The diagnostic claims sensitivity above 97% and specificity above 93%, with results available in days rather than the typical 7-10 year diagnostic delay associated with endometriosis. Ziwig operates a vertically integrated ecosystem spanning Ziwig R&D (a research laboratory at the Institut du Cerveau, Pitié-Salpêtrière Hospital in Paris), Ziwig Lab (an industrial production facility in Tercis-les-Bains capable of processing 4,500 tests per week via the world's only fully robotized salivary RNA extraction line), Ziwig Connect (a digital platform for health data integration), and Ziwig Care (a healthcare professional network).

The company's business model centers on B2B2C distribution of Ziwig Endotest® as a prescription-only in vitro diagnostic, sold through medical laboratories and gynecologists, with pricing not publicly disclosed and conducted on a quote basis. Commercial launch in France is scheduled for 2025 following French National Health Authority (HAS) early access validation and CE certification. The company also offers customized sequencing solutions to healthcare establishments, public health institutions, and biopharmaceutical firms through Ziwig Lab. Revenue had not commenced prior to 2025 per company disclosures. Distribution combines direct enterprise sales via the Ziwig Care network in France with international channel partners and clinical trial-driven market entry across Europe (Belgium, Switzerland), North Africa (Tunisia), and broader international geographies via the GYNARN study spanning 10 countries.

Ziwig is led by founder and Chairman Yahya El Mir (a chemist and entrepreneur) and CEO Julien Perrier (appointed 2025 with international pharmaceutical and biotech experience). The company has secured strategic technology partnerships with Revvity, Illumina, and Qiagen for production automation and sequencing platforms, alongside research partnerships with the Institut du Cerveau, CNGOF, and SIFEM. Government backing comes via the France 2030 investment program. The technology has earned notable recognition including Prix Galien International 2024 for Best Medical Technology, Prix Galien National 2022, EY Entrepreneur of the Year Auvergne-Rhône-Alpes 2024, and publication in NEJM Evidence (2023 and 2025). The clinical pipeline extends beyond endometriosis toward gynecological cancers and neurodegenerative diseases, leveraging the same salivary RNA platform.

Short descriptiontext

Ziwig is a Lyon-based French biotech company that has developed Ziwig Endotest®, the first saliva-based in vitro diagnostic for endometriosis, using proprietary microRNA analysis combined with next-generation sequencing and AI. The company serves women aged 18-43 with suspected endometriosis symptoms through gynecologists, medical laboratories, and the Ziwig Care network, with commercial launch in France from 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endometriosis diagnostics, salivary RNA testing, molecular diagnostic devices, women's health diagnostics, in vitro diagnostics
Industry5 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Ziwig Endotest Diagnostic Sales
TypeOne Time License
Description

Revenue from the sale of Ziwig Endotest, an in vitro diagnostic medical device for endometriosis diagnosis using saliva samples. The test is available by medical prescription only and is performed in laboratories. Revenue projections set to begin in 2025.

ziwig.com
2Customized Sequencing Solutions
TypeProfessional Services
Description

Ziwig Lab offers customized sequencing solutions to healthcare establishments, public health institutions and companies in the biopharmaceutical sector, meeting challenges of quality, reproducibility, reduced costs and rapid turnaround.

ziwig.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1Ziwig Endotest diagnostic test for endometriosis
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed. Quote-based sales through healthcare professionals and medical laboratories. Test is covered under early access procedure by French National Health Authority (HAS).

ziwig.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 8 records shown
1Ziwig Endotest®
Description

Salivary diagnostic test for endometriosis using miRNA analysis and artificial intelligence

ziwig.com:443
+7 more records
Core offering1 text field

Ziwig develops and commercializes Ziwig Endotest®, a CE-marked in vitro diagnostic medical device that diagnoses endometriosis from a saliva sample using high-throughput sequencing of salivary microRNAs combined with AI modeling. The company operates an integrated ecosystem spanning an R&D laboratory at Institut du Cerveau in Paris, an industrial production facility (Ziwig Lab) in Tercis-les-Bains, and a digital platform (Ziwig Connect) supporting clinical research, production, and care coordination.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Sensitivity >97%, Specificity >93%
+3 more records
Product overview1 text field

Ziwig offers a unified diagnostic ecosystem centered on Ziwig Endotest®, an in vitro diagnostic device for endometriosis diagnosis using salivary RNA analysis combined with AI. The portfolio includes Ziwig R&D (research laboratory at Institut du Cerveau in Paris) for fundamental molecular biology research, Ziwig Lab (industrial production facility in Tercis-les-Bains) for scalable manufacturing processing up to 4,500 tests weekly, Ziwig Connect (digital platform) for integrating health data across research, clinical trials, and patient services, and Ziwig Care (healthcare coordination network) for connecting patients with endometriosis care facilities.

Product and service2 records
1Ziwig Endotest®
CategoryMolecular Diagnostics / IVD Medical Device
Description

CE-marked in vitro diagnostic medical device for endometriosis that uses a saliva sample analyzed via high-throughput sequencing of salivary microRNAs combined with AI to deliver diagnostic results in a few days, with sensitivity above 97% and specificity above 93%. It is reserved for professional healthcare use, prescribed by clinicians, and performed in partner laboratories.

2Customized Sequencing Solutions (Ziwig Lab)
CategorySequencing Services / Laboratory Services
Description

Customized salivary RNA sequencing services offered to healthcare establishments, public health institutions, and biopharmaceutical companies via Ziwig Lab, leveraging a fully robotized extraction line and NGS platform with capacity of up to 4,500 tests per week to meet quality, reproducibility, cost, and turnaround-time requirements.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeTechnology or Integration
Description

Strategic technology partnership for the fully robotized salivary RNA analysis chain. Revvity provides technology integration at every stage of the production process, ensuring optimal quality, reproducibility, flexibility and efficiency.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership for next-generation sequencing technology integration. Illumina provides the sequencing platform used in the diagnostic process, enabling high-throughput RNA analysis with precision.

Strategic tierCoreTypeTechnology or Integration
Description

Industrial reference partner for diagnostic production. Qiagen contributes to the production standards of Ziwig's diagnostics ensuring quality and reliability.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Home to Ziwig R&D laboratory. The Brain Institute at Pitié-Salpêtrière Hospital provides the research facility for fundamental research in molecular biology and next-generation sequencing. Critical contribution to R&D activities.

5ProjectEndo.org
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for distribution of the Below the Belt documentary in France. Ziwig Foundation partners with ProjectEndo.org to support awareness and education about endometriosis through the documentary.

ziwig.com
6Endomind France
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient association representing women with endometriosis in France. Partner in awareness initiatives and patient advocacy for endometriosis awareness and care improvement.

ziwig.com
7Fibrome Info France
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient association dedicated to uterine fibroids, the number one disease affecting women. Partner in women's health education and awareness initiatives.

ziwig.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Official representative organization of obstetricians gynecologists in France. Provides scientific and operational expertise while respecting total independence and ethical requirements. Partner in improving care pathways and promoting innovative medical practices.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Professional society for women's imaging. Contributes scientific and operational expertise in endometriosis diagnosis through imaging, working to improve care pathways.

Strategic tierCoreTypeOthers
Description

Cloud infrastructure provider certified as Health Data Host (Hébergeur de Données de Santé - HDS) for secure hosting of health data. Provides secure data storage compliant with French health data regulations.

11Ziwig Lab
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Industrial partner laboratory located in Tercis-les-Bains, Landes. First molecular medical biology laboratory specializing in salivary RNA analysis with fully robotized production line. Processes up to 4,500 tests per week.

ziwig.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

dotLab develops molecular diagnostics for endometriosis, including a blood-based microRNA biomarker test (dotEndo). It is the closest direct competitor to Ziwig Endotest®, targeting the same patient population with a similar non-invasive molecular approach.

TypeBroad incumbent
Description

Hologic is a large women's health diagnostics and medical device company offering a broad portfolio including molecular diagnostics, imaging, and surgical solutions. Its scale and existing gynecology sales channels make it a likely competitive incumbent if endometriosis molecular diagnostics scale.

TypeBroad incumbent
Description

Myriad Genetics is an established molecular diagnostics company known for hereditary cancer and women's health tests. Its commercial infrastructure and payer relationships in women's health position it as a broad incumbent relevant to Ziwig's pipeline expansion beyond endometriosis.

TypeBroad incumbent
Description

Veracyte is a genomic diagnostics company specializing in molecular tests across urology, thyroid, and women's health. Its expertise in RNA-based diagnostics and securing reimbursement for novel molecular tests makes it a directly relevant broad incumbent peer.

TypeBroad incumbent
Description

Natera is a molecular diagnostics company with strong presence in reproductive health (non-invasive prenatal testing, carrier screening, oncology). Its women's health commercial reach and molecular diagnostic expertise make it a comparable broad incumbent.

TypeEmerging player
Description

MDNA Life Sciences develops molecular diagnostic tests based on mitochondrial DNA biomarkers, with applications in women's health including endometriosis. It is an emerging player addressing similar unmet diagnostic needs via novel molecular approaches.

TypeBroad incumbent
Description

ReproSource, integrated into Quest Diagnostics, specialized in reproductive medicine diagnostics. Quest's national clinical laboratory network and reproductive health offerings provide broad market reach for women's health molecular diagnostics.

TypeBroad incumbent
Description

CooperSurgical is a major women's health medical device and fertility company offering diagnostic, surgical, and ART products. Its strong gynecology channel relationships make it strategically relevant as Ziwig scales commercial access to practitioners.

TypeOthers
Description

Eurofins Genomics is a global genomics services provider offering sequencing, genotyping, and molecular biology services. As an established CDMO/service provider with deep European footprint, it represents a potential partner or competitive sequencing-services alternative to Ziwig Lab.

TypeOthers
Description

Illumina is a core technology partner of Ziwig for NGS platforms and could be considered both an enabler and a competitive threat if it vertically integrates into clinical diagnostics for endometriosis. Its dominance in sequencing infrastructure is directly relevant to Ziwig's production economics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ziwig

Molecular Diagnosticsziwig.com

Ziwig is a Lyon-based French biotech company that has developed Ziwig Endotest®, the first saliva-based in vitro diagnostic for endometriosis, using proprietary microRNA analysis combined with next-generation sequencing and AI. The company serves women aged 18-43 with suspected endometriosis symptoms through gynecologists, medical laboratories, and the Ziwig Care network, with commercial launch in France from 2025.

What Ziwig does

Ziwig is a French biotech company founded in 2019 and headquartered in Lyon, France, specializing in women's health diagnostics through salivary RNA analysis combined with artificial intelligence. The company's flagship product, Ziwig Endotest®, is the first in vitro diagnostic medical device for endometriosis using a saliva sample, employing a proprietary 109-miRNA signature analyzed via next-generation sequencing (NGS) and interpreted by machine learning algorithms. The diagnostic claims sensitivity above 97% and specificity above 93%, with results available in days rather than the typical 7-10 year diagnostic delay associated with endometriosis. Ziwig operates a vertically integrated ecosystem spanning Ziwig R&D (a research laboratory at the Institut du Cerveau, Pitié-Salpêtrière Hospital in Paris), Ziwig Lab (an industrial production facility in Tercis-les-Bains capable of processing 4,500 tests per week via the world's only fully robotized salivary RNA extraction line), Ziwig Connect (a digital platform for health data integration), and Ziwig Care (a healthcare professional network).

The company's business model centers on B2B2C distribution of Ziwig Endotest® as a prescription-only in vitro diagnostic, sold through medical laboratories and gynecologists, with pricing not publicly disclosed and conducted on a quote basis. Commercial launch in France is scheduled for 2025 following French National Health Authority (HAS) early access validation and CE certification. The company also offers customized sequencing solutions to healthcare establishments, public health institutions, and biopharmaceutical firms through Ziwig Lab. Revenue had not commenced prior to 2025 per company disclosures. Distribution combines direct enterprise sales via the Ziwig Care network in France with international channel partners and clinical trial-driven market entry across Europe (Belgium, Switzerland), North Africa (Tunisia), and broader international geographies via the GYNARN study spanning 10 countries.

Ziwig is led by founder and Chairman Yahya El Mir (a chemist and entrepreneur) and CEO Julien Perrier (appointed 2025 with international pharmaceutical and biotech experience). The company has secured strategic technology partnerships with Revvity, Illumina, and Qiagen for production automation and sequencing platforms, alongside research partnerships with the Institut du Cerveau, CNGOF, and SIFEM. Government backing comes via the France 2030 investment program. The technology has earned notable recognition including Prix Galien International 2024 for Best Medical Technology, Prix Galien National 2022, EY Entrepreneur of the Year Auvergne-Rhône-Alpes 2024, and publication in NEJM Evidence (2023 and 2025). The clinical pipeline extends beyond endometriosis toward gynecological cancers and neurodegenerative diseases, leveraging the same salivary RNA platform.

Ziwig firmographics

Firmographics
Name
Ziwig
Legal name
ZIWIG
Website
https://ziwig.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Ziwig is a Lyon-based French biotech company that has developed Ziwig Endotest®, the first saliva-based in vitro diagnostic for endometriosis, using proprietary microRNA analysis combined with next-generation sequencing and AI. The company serves women aged 18-43 with suspected endometriosis symptoms through gynecologists, medical laboratories, and the Ziwig Care network, with commercial launch in France from 2025.
Ownership category
akta.pro rank

Ziwig industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Equipment and Supplies Manufacturing (3391), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Endometriosis diagnostics
  • Salivary RNA testing
  • Molecular diagnostic devices
  • Women's health diagnostics
  • In vitro diagnostics

Where Ziwig is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Ziwig business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Ziwig Endotest Diagnostic Sales: Revenue from the sale of Ziwig Endotest, an in vitro diagnostic medical device for endometriosis diagnosis using saliva samples. The test is available by medical prescription only and is performed in laboratories. Revenue projections set to begin in 2025.
  2. Customized Sequencing Solutions: Ziwig Lab offers customized sequencing solutions to healthcare establishments, public health institutions and companies in the biopharmaceutical sector, meeting challenges of quality, reproducibility, reduced costs and rapid turnaround.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goZiwig Endotest diagnostic test for endometriosis

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Ziwig product offering

Product offering

Core offering

Ziwig develops and commercializes Ziwig Endotest®, a CE-marked in vitro diagnostic medical device that diagnoses endometriosis from a saliva sample using high-throughput sequencing of salivary microRNAs combined with AI modeling. The company operates an integrated ecosystem spanning an R&D laboratory at Institut du Cerveau in Paris, an industrial production facility (Ziwig Lab) in Tercis-les-Bains, and a digital platform (Ziwig Connect) supporting clinical research, production, and care coordination.

Product overview

Ziwig offers a unified diagnostic ecosystem centered on Ziwig Endotest®, an in vitro diagnostic device for endometriosis diagnosis using salivary RNA analysis combined with AI. The portfolio includes Ziwig R&D (research laboratory at Institut du Cerveau in Paris) for fundamental molecular biology research, Ziwig Lab (industrial production facility in Tercis-les-Bains) for scalable manufacturing processing up to 4,500 tests weekly, Ziwig Connect (digital platform) for integrating health data across research, clinical trials, and patient services, and Ziwig Care (healthcare coordination network) for connecting patients with endometriosis care facilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Ziwig Endotest®: Salivary diagnostic test for endometriosis using miRNA analysis and artificial intelligence
  • Ziwig Connect
  • Ziwig Lab
  • Ziwig R&D
  • Ziwig Care
  • Ziwig Foundation
  • Endo'Lives
  • Precision for Women

Products and services

  • Ziwig Endotest® CE-marked in vitro diagnostic medical device for endometriosis that uses a saliva sample analyzed via high-throughput sequencing of salivary microRNAs combined with AI to deliver diagnostic results in a few days, with sensitivity above 97% and specificity above 93%. It is reserved for professional healthcare use, prescribed by clinicians, and performed in partner laboratories.
  • Customized Sequencing Solutions (Ziwig Lab) Customized salivary RNA sequencing services offered to healthcare establishments, public health institutions, and biopharmaceutical companies via Ziwig Lab, leveraging a fully robotized extraction line and NGS platform with capacity of up to 4,500 tests per week to meet quality, reproducibility, cost, and turnaround-time requirements.

Quantifiable outcome

  • Sensitivity >97%, Specificity >93%
  • +3 more outcomes

Companies that use Ziwig

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Ziwig technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Ziwig partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • RevvitycoreTechnology or IntegrationStrategic technology partnership for the fully robotized salivary RNA analysis chain. Revvity provides technology integration at every stage of the production process, ensuring optimal quality, reproducibility, flexibility and efficiency.
  • IlluminacoreTechnology or IntegrationPartnership for next-generation sequencing technology integration. Illumina provides the sequencing platform used in the diagnostic process, enabling high-throughput RNA analysis with precision.
  • QiagencoreTechnology or IntegrationIndustrial reference partner for diagnostic production. Qiagen contributes to the production standards of Ziwig's diagnostics ensuring quality and reliability.
  • Institut du Cerveau (Brain Institute)coreStrategic or Co-development PartnerHome to Ziwig R&D laboratory. The Brain Institute at Pitié-Salpêtrière Hospital provides the research facility for fundamental research in molecular biology and next-generation sequencing. Critical contribution to R&D activities.
  • ProjectEndo.orgminorStrategic or Co-development PartnerPartnership for distribution of the Below the Belt documentary in France. Ziwig Foundation partners with ProjectEndo.org to support awareness and education about endometriosis through the documentary.
  • Endomind FranceminorStrategic or Co-development PartnerPatient association representing women with endometriosis in France. Partner in awareness initiatives and patient advocacy for endometriosis awareness and care improvement.
  • Fibrome Info FranceminorStrategic or Co-development PartnerPatient association dedicated to uterine fibroids, the number one disease affecting women. Partner in women's health education and awareness initiatives.
  • Collège National des Gynécologues Obstétriciens (CNGOF)coreStrategic or Co-development PartnerOfficial representative organization of obstetricians gynecologists in France. Provides scientific and operational expertise while respecting total independence and ethical requirements. Partner in improving care pathways and promoting innovative medical practices.
  • Société d'Imagerie de la Femme (SIFEM)coreStrategic or Co-development PartnerProfessional society for women's imaging. Contributes scientific and operational expertise in endometriosis diagnosis through imaging, working to improve care pathways.
  • Amazon Web Services (AWS)coreOthersCloud infrastructure provider certified as Health Data Host (Hébergeur de Données de Santé - HDS) for secure hosting of health data. Provides secure data storage compliant with French health data regulations.
  • Ziwig LabcoreStrategic or Co-development PartnerIndustrial partner laboratory located in Tercis-les-Bains, Landes. First molecular medical biology laboratory specializing in salivary RNA analysis with fully robotized production line. Processes up to 4,500 tests per week.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Ziwig competitors and assessment

Company assessment

Direct peers

  • dotLab: dotLab develops molecular diagnostics for endometriosis, including a blood-based microRNA biomarker test (dotEndo). It is the closest direct competitor to Ziwig Endotest®, targeting the same patient population with a similar non-invasive molecular approach.

Broad incumbents

  • Hologic: Hologic is a large women's health diagnostics and medical device company offering a broad portfolio including molecular diagnostics, imaging, and surgical solutions. Its scale and existing gynecology sales channels make it a likely competitive incumbent if endometriosis molecular diagnostics scale.
  • Myriad Genetics: Myriad Genetics is an established molecular diagnostics company known for hereditary cancer and women's health tests. Its commercial infrastructure and payer relationships in women's health position it as a broad incumbent relevant to Ziwig's pipeline expansion beyond endometriosis.
  • Veracyte: Veracyte is a genomic diagnostics company specializing in molecular tests across urology, thyroid, and women's health. Its expertise in RNA-based diagnostics and securing reimbursement for novel molecular tests makes it a directly relevant broad incumbent peer.
  • Natera: Natera is a molecular diagnostics company with strong presence in reproductive health (non-invasive prenatal testing, carrier screening, oncology). Its women's health commercial reach and molecular diagnostic expertise make it a comparable broad incumbent.
  • ReproSource (now part of Quest Diagnostics): ReproSource, integrated into Quest Diagnostics, specialized in reproductive medicine diagnostics. Quest's national clinical laboratory network and reproductive health offerings provide broad market reach for women's health molecular diagnostics.
  • CooperSurgical: CooperSurgical is a major women's health medical device and fertility company offering diagnostic, surgical, and ART products. Its strong gynecology channel relationships make it strategically relevant as Ziwig scales commercial access to practitioners.

Emerging players

  • MDNA Life Sciences: MDNA Life Sciences develops molecular diagnostic tests based on mitochondrial DNA biomarkers, with applications in women's health including endometriosis. It is an emerging player addressing similar unmet diagnostic needs via novel molecular approaches.

Others

  • Eurofins Genomics: Eurofins Genomics is a global genomics services provider offering sequencing, genotyping, and molecular biology services. As an established CDMO/service provider with deep European footprint, it represents a potential partner or competitive sequencing-services alternative to Ziwig Lab.
  • Illumina: Illumina is a core technology partner of Ziwig for NGS platforms and could be considered both an enabler and a competitive threat if it vertically integrates into clinical diagnostics for endometriosis. Its dominance in sequencing infrastructure is directly relevant to Ziwig's production economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ziwig social profiles

Digital presence

Ziwig compliance and trust

Trust signal

Compliance4 records

Ziwig financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ziwig leadership team

Management profile

Number of profiles

Profiles3 records

Ziwig subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Ziwig funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ziwig M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ziwig

What does Ziwig do?

Ziwig develops and commercializes Ziwig Endotest®, a CE-marked in vitro diagnostic medical device that diagnoses endometriosis from a saliva sample using high-throughput sequencing of salivary microRNAs combined with AI modeling. The company operates an integrated ecosystem spanning an R&D laboratory at Institut du Cerveau in Paris, an industrial production facility (Ziwig Lab) in Tercis-les-Bains, and a digital platform (Ziwig Connect) supporting clinical research, production, and care coordination.

Is Ziwig a public or private company?

Ziwig is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ziwig founded?

Ziwig was founded in 2020. It employs 51 to 100 people.

Where is Ziwig based?

Ziwig is headquartered in Lyon, France, in the Europe region.

How does Ziwig make money?

Two revenue lines are on record. Ziwig Endotest Diagnostic Sales are the primary driver. The others are customized Sequencing Solutions.

Who are Ziwig's main competitors?

dotLab is listed as a direct peer. Broad incumbents are Hologic, Myriad Genetics, Veracyte, Natera, ReproSource (now part of Quest Diagnostics) and CooperSurgical. MDNA Life Sciences is listed as an emerging player. Others are Eurofins Genomics and Illumina.

Does Ziwig have an API?

No public API is recorded for Ziwig.

What industry is Ziwig in?

Ziwig's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 3391 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Global NewsRapid endometriosis tests now available in the U.K. What about Canada? - NationalThe U.K. approved two non-invasive endometriosis diagnostic tests—Endotest by Ziwig and EndoSure—on July 7, marking the first such authorizations globally. Ziwig has stated it is actively engaging with potential local partners to make Endotest commercially available in Canada, where Health Canada has not yet approved either test. Provincial and territorial health ministries have responded with varying levels of interest, while experts note that endometriosis diagnosis in Canada currently takes an average of five years or longer.ABCSaliva test for endometriosis lacks real-world evidence, Australian experts sayAustralian medical experts are cautioning against introducing the Ziwig Endotest, a saliva-based test for endometriosis, citing insufficient real-world evidence despite its growing social media attention. The French start-up's test, which costs approximately $2,000 and claims 97% accuracy, is currently available only through specialist-led trials in France and the UK; no application has been made to Australia's medicines regulator for local trials. Experts recommend existing diagnostic methods such as transvaginal ultrasound while ongoing large-scale trials in France and the UK validate the test's efficacy.YahooNICE greenlights first non-invasive endometriosis diagnostic toolsNICE, the UK's National Institute for Health and Care Excellence, has recommended two non-invasive endometriosis diagnostic tests (EndoSure and Ziwig Endotest) for use across Britain's NHS, aiming to reduce the average nine-year wait time for diagnosis. EndoSure detects electrical signals in the gut with 98-99% accuracy providing immediate results, while Ziwig Endotest screens saliva samples for 109 microRNAs associated with the condition with results available in two to three weeks. Both tools offer a less invasive diagnostic approach that could allow for earlier treatment and reduce the need for invasive surgical procedures.Medical Device NetworkNICE greenlights first non-invasive endometriosis diagnostic toolsNICE has issued draft guidance recommending two non-invasive endometriosis diagnostic tests, EndoSure and Ziwig Endotest, for use across the NHS for an initial three-year period. EndoSure uses abdominal sensor pads to detect electrical signals associated with endometriosis with 98-99% accuracy, while Ziwig Endotest analyzes a saliva sample through next-generation sequencing to identify 109 microRNAs linked to the condition, with results available within two to three weeks. The introduction aims to address the current average wait time of over nine years for endometriosis diagnosis in the UK, where many patients currently require invasive keyhole surgery for a definitive diagnosis.PR NewswireZiwig Endotest®: Scientific Validation Published in NEJM EvidenceZiwig's saliva-based diagnostic test, Ziwig Endotest®, for endometriosis has been validated through a multicenter clinical study published in NEJM Evidence. The test demonstrated high accuracy with 97.3% sensitivity and 94.1% specificity in a study of 971 women across France. Consequently, the test is now reimbursed and available on prescription in 100 hospitals under France's national early access program.PR NewswireZiwig Endotest®: Scientific Validation Published in NEJM EvidenceZiwig's saliva-based diagnostic test for endometriosis, Ziwig Endotest®, was validated in a multicenter clinical study published in NEJM Evidence. The study of 971 women demonstrated high diagnostic accuracy, leading to the test's reimbursement and availability via prescription in French hospitals under the national early access program.Le Monde.frFrench startup brings endometriosis saliva test one step closer to reimbursementFrench health authority HAS issued an opinion on Ziwig's saliva test for endometriosis, citing good diagnostic performance but lacking clinical usefulness data. The test costs about €800 and is proposed for controlled access via an innovation package, pending a study of its effectiveness.